Healthcare system selects UltraSPECT nuclear medicine software for lowering dose and reducing exam time.

In vitro drug trials could get a boost from a micrometer-small molecular imaging system that captures cells and tests their response to a miniscule flood of radiopharmaceuticals, according to a study published Aug. 26 in the Journal of Nuclear Medicine.

At least 14 new molecular imaging agents are being groomed for clinical use, with approval of three major radiotracers expected by 2016, according to an Aug. 2013 GlobalData report entitled “The Future of Molecular Imaging.”

First Warning Systems, Inc. (FWS), a Reno-based life sciences software and medical device company, recently retained Joshua D. I. Ellenhorn, M.D., as the Principal Investigator (PI) in preparation for the anticipated clinical validation studies slated for later this year. This is the latest development in FWS’ progress toward the realization of its non-invasive, intelligent, wearable, biofeedback early breast cancer screening device. Retention of an expert PI is a critical step toward bringing FWS’ proprietary breast health product and service to market in the near term.

Injured soldiers returning from combat now have access to more advanced and comfortable MR technology with Toshiba’s Vantage TitanTM 3T MR. Winn Army Community Hospital, a TRICARE military treatment facility in Fort Stewart, Ga., installed the system for general, musculoskeletal and body imaging. This acquisition marks the 1,600th Vantage MR installed worldwide and the 500th installed in the U.S.

FDG PET/CT imaging prior to osteosarcoma surgery and chemotherapy may be able to provide a clearer picture of patient risk and prognosis, according to a study published Aug. 15 in the Journal of Nuclear Medicine.

The neuromodulator adenosine and its interaction with a receptor known as A2A are being implicated in a range of brain diseases, including Parkinson’s and Huntington’s, as well as a spate of psychiatric disorders. A novel SPECT agent has been found to successfully shine a spotlight on this relationship, according to research published Aug. 22 in the Journal of Nuclear Medicine.

Researchers are forever seeking to outsmart therapy-resistant cancers. "No Through Road," a feature published Aug. 5 in Cancer Today, a publication of the American Association for Cancer Research, highlights just this quest.